Xencor - XNCR Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings or view top-rated stocks.

9 analysts have issued 1-year target prices for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $60.00. On average, they expect the company's share price to reach $48.89 in the next twelve months. This suggests a possible upside of 66.9% from the stock's current price.
View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts.

Xencor's stock was trading at $40.12 at the beginning of 2022. Since then, XNCR shares have decreased by 27.0% and is now trading at $29.29.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our XNCR earnings forecast.

Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.06. The biopharmaceutical company earned $19.68 million during the quarter, compared to the consensus estimate of $17.63 million. Xencor had a net margin of 10.07% and a trailing twelve-month return on equity of 4.04%. During the same quarter last year, the firm earned ($0.22) EPS.

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Xencor's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.70%), Vanguard Group Inc. (10.95%), Primecap Management Co. CA (9.50%), State Street Corp (5.43%), Price T Rowe Associates Inc. MD (5.36%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends.

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XNCR stock can currently be purchased for approximately $29.29.

Xencor (NASDAQ:XNCR) has a market capitalization of $1.76 billion and generates $275.11 million in revenue each year. The biopharmaceutical company earns $82.63 million in net income (profit) each year or $0.48 on an earnings per share basis.

The company employs 254 workers across the globe.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.